https://www.aigom.it/wp-content/uploads/2025/05/ART27MAGGIO.png1411960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-27 08:00:382025-05-27 08:00:38PEMBROLIZUMAB AND CHEMOTHERAPY IN HIGH-RISK, EARLY-STAGE, ER+/HER2-BREAST CANCER: A RANDOMIZED PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-23 12:30:392025-05-23 12:31:22PRESENTAZIONI BIOMARCATORI E CARCINOMA MAMMARIO 22 MAGGIO 2025
https://www.aigom.it/wp-content/uploads/2025/05/ART20.5.png1254841Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-20 09:51:122025-05-20 09:51:12DIAGNOSIS AND MANAGEMENT OF INFECTIONS CAUSED BY MULTIDRUG-RESISTANT BACTERIA: GUIDELINE ENDORSED BY ITALIAN SOCIETY OF INFECTION AND TROPICAL DISEASES (SIMIT), THE ITALIAN SOCIETY OF ANTI-INFECTIVE THERAPY (SITA), THE ITALIAN GROUP FOR ANTIMICROBIAL STEWARDSHIP (GISA), THE ITALIAN ASSOCIATION OF CLINICAL MICROBIOLOGIST (AMCLI) AND THE ITALIAN SOCIETY OF MICROBIOLOGY (SIM).
https://www.aigom.it/wp-content/uploads/2025/05/ART13.5.png1273960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-13 10:38:432025-05-13 10:38:43OlympiA: A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ADJUVANT OLAPARIB AFTER (NEO)ADJUVANT CHEMOTHERAPY IN PATIENTS WITH GERMLINE BRCA1 AND/OR BRCA2 PATHOGENIC VARIANTS AND HIGH RISK HER2-NEGATIVE PRIMARY BREAST CANCER: LONGER TERM FOLLOW-UP
https://www.aigom.it/wp-content/uploads/2025/05/Screenshot-2025-05-06-102711.png1046752Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-06 09:01:132025-05-16 08:17:26NEGRAR DI VALPOLICELLA (VE)-SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA 2025-11° EDIZIONE VENERDI 16-SABATO 17 MAGGIO 2025
https://www.aigom.it/wp-content/uploads/2025/05/ART6MAGGIO.png1284923Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-05-06 08:45:352025-05-06 08:45:35FIRST-LINE MOBOCERTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH EGFR EXON 20 INSERTION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER IN THE PHASE III EXCLAIM-2 TRIAL
